Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study
MedComm – Oncology · 2025-03 · 4 (1)
DOI: 10.1002/mog2.70013 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift MedComm – Oncology, online erschienen am 04.03.2025. Verfasst von Hanchuan Shen und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Shen, H., Liu, B., Zhang, H., Liu, Y., & Li, C. (2025). Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study. MedComm – Oncology, 4(1). https://doi.org/10.1002/mog2.70013
Vancouver
Shen H, Liu B, Zhang H, Liu Y, Li C. Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study. MedComm – Oncology. 2025;4(1). doi:10.1002/mog2.70013
BibTeX
@article{Shen2025,
author = {Shen, Hanchuan and Liu, Bing and Zhang, Hangyu and Liu, Yang and Li, Chenggang},
title = {Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study},
journal = {MedComm – Oncology},
year = {2025},
volume = {4},
number = {1},
doi = {10.1002/mog2.70013}
}
EUVIMED